Interestingly, some FDA approved Gal-3 inhibitors such as TD139 (from Galecto Biotech) in idiopathic pulmonary fibrosis or GM-CT-01 and GR-MD-02 (both from Galectin Therapeutics) in metastatic melanoma were found safe and well-tolerated by patients (clinical trials registered in clinicaltrials.gov: NCT03832946, NCT02117362, and NCT01723813, respectively). This evidence concerns the gene LGALS3 and idiopathic pulmonary fibrosis.